Sinopharm announces leadership changes, proposes new directors

Sinopharm Group Co. Ltd. announced on November 28, 2025, that Zhao Bingxiang has tendered his resignation as a non-executive director, chairman of the board, chairman of the nomination committee, chairman of the strategy and investment committee, a member of the legal and compliance and environmental, social and governance committee, and the authorized representative. Concurrently, Feng Rongli has resigned as a non-executive director and a member of both the remuneration committee and nomination committee. These resignations are effective upon the appointment of their respective replacements.

The board resolved to propose the appointment of Jin Bin and Li Ying as new non-executive directors. Jin Bin, aged 52, currently serves as the deputy general manager, general legal counsel, and chief compliance officer of CNPGC. Li Ying, also 52, is the deputy general manager of the first asset management department of China CITIC Financial Asset Management Co., Ltd., bringing extensive experience in equity investment within the pharmaceutical industry. Their appointments are subject to shareholder approval at an extraordinary general meeting.

Furthermore, Jin Bin is proposed to be elected as the new chairman and authorized representative, along with assuming chairmanships of the nomination committee and the strategy and investment committee, and a membership in the legal and compliance and environmental, social and governance committee. The register of members will be closed from December 16, 2025, to December 19, 2025, for an extraordinary general meeting to approve these changes.